Browsing: Weight Loss

Eli Lilly (NYSE: LLY) is a Wall Street darling thanks to its success in the GLP-1 weight-loss market. There’s a problem here, however, because weight-loss drugs now account for nearly two-thirds of the drug maker’s revenues. Johnson & Johnson (NYSE: JNJ) CEO Joaquin Duato isn’t interested in being so reliant on just one healthcare niche.…

July 5, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today recent submissions of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for ASC36, a once-monthly to once-quarterly next-generation peptide amylin receptor agonist and ASC36_35 FDC, a once-monthly injection co-formulation of ASC36 plus peptide GLP-1R/GIPR agonist ASC35,…